|
Jul 16
|
CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY
|
|
Jul 7
|
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
|
|
Jul 7
|
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
|
|
Jul 2
|
Cyclacel Pharmaceuticals Announces Stock Split
|
|
Jun 20
|
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock
|
|
Apr 2
|
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
|
|
Jan 3
|
Cyclacel Pharmaceuticals Says David Lazar Buys $3.1 Million in Preferred Stock, Becomes Interim CEO
|
|
Jan 3
|
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
|
|
Oct 9
|
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
|
|
Aug 18
|
Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Jul 25
|
Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know
|
|
Jun 26
|
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
|
|
Apr 1
|
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
|
|
Dec 22
|
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
|
|
Dec 18
|
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
|
|
Dec 12
|
Cyclacel Pharmaceuticals Announces Reverse Stock Split
|
|
Nov 30
|
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
|
|
Nov 29
|
Health Care Roundup: Market Talk
|
|
Nov 28
|
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
|
|
Nov 14
|
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript
|